Signalling Molecules as Targets in Cancer TherapyThis book presents state-of-the-art information on the molecules of cell signalling pathways that represent actual or future targets for cancer therapy. By giving an update of the most promising approaches in this rapidly evolving field, the book contributes to the translation of the recent advances in the knowledge of intracellular signalling into the generation of innovative biomolecules as specific tools to target the most promising tumour-specific candidates. The book begins logically with the molecules first encountered along the signalling pathways, the membrane receptors for growth factors (Part I). Next, Part II presents several examples of intracellular molecular targets that are situated one step beyond in the pathways, while Part III addresses the difficult task of tuning the delicate balance between cell death and survival. In Part IV, the reader is taken into the practical problems raised by the therapy of specific cancers (glioma, childhood leukaemia), and into an original strategy from the field of nuclear medicine with the potential to generate innovative molecular-targeted cancer therapies. |
Contents
| 3 | |
The RET ProtoOncogene A Valuable Target for Thyroid Cancer Therapy | 21 |
Inhibitors of HERErbB Receptors Biological Bases and Clinical Applications | 35 |
Targeting Intracellular Molecules | 67 |
Phosphatases as Promising Targets for Cancer Therapy | 69 |
Targeting the mTOR Pathway for Cancer Therapy | 87 |
Targeting MAP Kinase Signaling Pathways for the Treatment of Cancer | 109 |
Targeting Apoptosis | 141 |
Cell DeathBased Therapy | 143 |
Part IV Strategies for Drug Development and Delivery | 163 |
Signaling Molecules and Therapeutic Targets in Gliomas | 165 |
Identifying and Targeting Genes Involved in Childhood Leukemia | 191 |
Receptor Binding Peptides for Receptor Mediated Endoradiotherapy in Oncology | 215 |
| 227 | |
Common terms and phrases
activity addition agents antibody apoptosis associated binding Biol biological block breast cancer cancer cells Cancer Res carcinoma caspase cell lines cellular chemotherapy chromosome Clin Oncol clinical clinical trials combination complex compounds death demonstrated disease domain dose drug E2A-HLF effects EGFR epidermal growth factor et al expression Figure function Gefitinib gene genetic glioblastoma glioma growth factor receptor human identified imatinib important increased induced inhibition intracellular involved Journal kinase inhibitor lead leukemia levels ligand lung cancer malignant mechanism mediated mice molecular molecules mTOR mutations Nature novel observed oncogenic overexpression patients peptides phase phosphatase phosphorylation platelet-derived growth factor potential present progression proliferation prostate protein protein kinase PTEN rapamycin recent regulation reported resistance response role selective shown signaling pathways specific studies suggest target therapeutic therapy transcription transformation translocation treatment tumor tumor suppressor tyrosine kinase